Could a daily shot slow PSP? new study tests long-term safety
NCT ID NCT06235775
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety of a daily injection called GV1001 in people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and balance. It included 67 patients who had already completed a previous GV1001 study. Researchers monitored side effects and lab results over 12 months to see if the drug remains safe for extended use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kyung Hee University Hospital
Seoul, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, South Korea
-
Seoul National University Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a brain disease change behavior years before diagnosis?
- High-Resolution brain scans aim to unmask Tau's role in Parkinson's
- Wearable sensors aim to catch neurodegenerative decline in real time
- Experimental antibody aims to tame rare brain disorder
- Scientists decode gait signatures to spot brain diseases
- Scientists hunt for clues to diagnose Parkinson's earlier